Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities

Orphazyme A/S

Company announcement                                                                              

No. 41/2020                                                                                                  

Company Registration No. 32266355

Copenhagen, Denmark, July 15, 2020 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:

1 Details of the Reporting Person / Closely Associated Person

a) Name

Kim Stratton

2 Reason for the notification

a) Position/status

Chief Executive Officer

b) Initial notification/Amendment

Initial notification

3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name

Orphazyme A/S

b) LEI code

54930025OZD2GGSQ7L42

4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a) Description of the financial instrument, type of instrument and identification code

Shares

ISIN DK0060910917

b) Nature of the transaction

Purchase of shares

c) Price(s) and volume(s)

d) Aggregated information

Aggregated volume: 8,000 shares

Aggregated price: DKK 748,798.00

Price per share (volume weighted average): DKK 93.59975

e) Date of the transaction

July 13, 2020

f) Place of the transaction

Nasdaq Copenhagen A/S – XCSE

For additional information, please contact

Orphazyme

Anders Vadsholt, CFO                            

About Orphazyme A/S 

Orphazyme is a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is focused on developing therapies for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Gaucher Disease, sporadic Inclusion Body Myositis (sIBM), and Amyotrophic Lateral Sclerosis (ALS). The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit . 

Forward-looking statement 

This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events, including the clinical development and potential benefits of arimoclomol for Gaucher disease, NPC, sIBM and ALS, are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof . Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.  

Attachment